🎯 check Navitoclax (ABT-263) product page
Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family inhibitor. It affects intrinsic apoptotic and MAPK signaling pathways by binding to anti-apoptotic Bcl-2/Bcl-xL proteins to release pro-apoptotic factors, effectively promoting apoptosis and clearing senescent and cancer cells.